- Home
- ODV vs FDMT Comparison
ODV vs FDMT Comparison
Compare ODV & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- FDMT
- Stock Information
- Founded
- ODV 2005
- FDMT 2013
- Country
- ODV Canada
- FDMT United States
- Employees
- ODV N/A
- FDMT N/A
- Industry
- ODV Precious Metals
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- FDMT Health Care
- Exchange
- ODV Nasdaq
- FDMT Nasdaq
- Market Cap
- ODV 239.0M
- FDMT 268.6M
- IPO Year
- ODV N/A
- FDMT 2020
- Fundamental
- Price
- ODV $1.58
- FDMT $4.58
- Analyst Decision
- ODV
- FDMT Buy
- Analyst Count
- ODV 0
- FDMT 11
- Target Price
- ODV N/A
- FDMT $41.70
- AVG Volume (30 Days)
- ODV 168.2K
- FDMT 1.1M
- Earning Date
- ODV 11-12-2024
- FDMT 02-27-2025
- Dividend Yield
- ODV N/A
- FDMT N/A
- EPS Growth
- ODV N/A
- FDMT N/A
- EPS
- ODV N/A
- FDMT N/A
- Revenue
- ODV $8,487,361.00
- FDMT $17,000.00
- Revenue This Year
- ODV N/A
- FDMT N/A
- Revenue Next Year
- ODV $595.27
- FDMT $159.49
- P/E Ratio
- ODV N/A
- FDMT N/A
- Revenue Growth
- ODV N/A
- FDMT N/A
- 52 Week Low
- ODV $1.34
- FDMT $4.50
- 52 Week High
- ODV $2.75
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- ODV 41.76
- FDMT 30.88
- Support Level
- ODV $1.54
- FDMT $4.68
- Resistance Level
- ODV $1.68
- FDMT $5.15
- Average True Range (ATR)
- ODV 0.08
- FDMT 0.43
- MACD
- ODV 0.00
- FDMT -0.05
- Stochastic Oscillator
- ODV 24.73
- FDMT 3.69
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation and development activities of its projects.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.